TCPI INC
10-Q, EX-27, 2000-11-14
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: TCPI INC, 10-Q, 2000-11-14
Next: SUMMIT LIFE CORP, 10QSB, 2000-11-14



<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
    (The Company's Quarterly Report on Form 10-Q for the Period Ending
September 30, 2000)
</LEGEND>
<CIK>                         0000924921
<NAME>                        Walter Usinowicz

<S>                             <C>
<PERIOD-TYPE>                        9-MOS
<FISCAL-YEAR-END>                    DEC-31-2000
<PERIOD-START>                       JAN-01-2000
<PERIOD-END>                         SEP-30-2000
<CASH>                                                         715
<SECURITIES>                                                     0
<RECEIVABLES>                                                  925
<ALLOWANCES>                                                   333
<INVENTORY>                                                  2,181
<CURRENT-ASSETS>                                             5,643
<PP&E>                                                       3,901
<DEPRECIATION>                                               2,058
<TOTAL-ASSETS>                                              21,821
<CURRENT-LIABILITIES>                                        4,279
<BONDS>                                                        557
                                            0
                                                  1,601
<COMMON>                                                        32
<OTHER-SE>                                                  14,325
<TOTAL-LIABILITY-AND-EQUITY>                                21,821
<SALES>                                                      3,314
<TOTAL-REVENUES>                                             3,514
<CGS>                                                        1,898
<TOTAL-COSTS>                                                1,898
<OTHER-EXPENSES>                                                 0
<LOSS-PROVISION>                                                 0
<INTEREST-EXPENSE>                                              85
<INCOME-PRETAX>                                             (6,796)
<INCOME-TAX>                                                     0
<INCOME-CONTINUING>                                         (6,796)
<DISCONTINUED>                                                   0
<EXTRAORDINARY>                                                  0
<CHANGES>                                                        0
<NET-INCOME>                                                (6,796)
<EPS-BASIC>                                                  (0.25)
<EPS-DILUTED>                                                (0.25)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission